Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.
Authors
Nashat Y. Gabrail
Gabrail Cancer Center, Canton, OH
Nashat Y. Gabrail , Anthony Tolcher , Olatunji B. Alese , Michael Cecchini , Patel Manish , Haeseong Park , Jordan Berlin , Erika P. Hamilton , Yingjie Huang , Lingmin Lu , Jianming Wang , Michael Shi , Ming F. Tong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.TPS375
Abstract #
TPS375
Poster Bd #
N3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.
First Author: Yelena Y. Janjigian
Poster
2023 ASCO Annual Meeting
A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.
First Author: Fei Ma
Poster
2023 ASCO Annual Meeting
Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors.
First Author: Sunil Sharma
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 1 first-in-human study of XL092 administered alone or in combination with immune checkpoint inhibitors (ICIs) in patients (pts) with inoperable locally advanced or metastatic solid tumors: Description of genitourinary (GU) expansion cohorts.
First Author: Manish Sharma